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Background: There is emerging evidence for the potential of computer-based psychological treatments (CBPT) as
an add-on to usual clinical practice in the management of health problems.
Objective: The study set out to observe if, when, and how clinicians working in a publically funded alcohol/other
drug (AOD) clinical service might utilize SHADE (Self-Help for Alcohol and other drug use and DEpression), a CBPT
program for comorbid depression and alcohol or cannabis use, in their clinical practice.
Methods: Thirteen clinicians working within an AOD service on the Central Coast of New South Wales, Australia,
were recruited. At baseline, all 13 clinicians were assessed for their computer anxiety and openness to innovation.
Clinicians referred current clients to the study, with consenting and eligible clients (N = 35) completing a baseline
and 15-week follow-up clinical assessment. The assessment comprised a range of mental health and AOD measures
administered by an independent research assistant. Over the course of the study, clinicians submitted session
checklists detailing information about session content, including the context and extent to which SHADE was used
for each client.
Results: Descriptive statistics showed that clinicians employed the SHADE program in a variety of ways. When
SHADE modules were used, they were generally introduced in the early phase of treatment, on average, around
session 4 (M = 3.77, SD = 5.26, range 1–36). However, only 12 of the 35 clients whose session checklists were
available were exposed to the SHADE modules; this, despite 28/35 clients indicating that they would be willing to
use CBPT during their current treatment program.
Conclusions: Treatment seekers in the AOD service of the current trial were generally open to receiving CBPT like
SHADE; however, clinicians tended to use SHADE with only 34 percent of clients. This indicates the importance of
providing ongoing support and encouragement to clinicians, in addition to an initial training session, to encourage
the adoption of innovative technologies into clinical practice, and perhaps to engage clients in a discussion about
CBPT more routinely.
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With the rise and global impact of mental health and
alcohol/other drug (AOD) use disorders, new avenues
for treatment have revealed the potential for technology
to respond to this increasing need. For example, a recent
meta-analysis of the use of internet/computerized interven-
tions for problem drinking [1] identified nine randomized
controlled trials (RCTs) attesting to the efficacy of these
treatment modalities in reducing alcohol use. Similarly, a
meta-analysis of computerized treatments for depression
and anxiety disorders [2] identified 22 RCTs demonstrating
that computer therapy for these disorders is effective and
acceptable.
There are many potential benefits of incorporating
computer-based psychological treatments (CBPT) into
community-based mental health services (including drug
and alcohol clinical services). The standardized nature of
automated treatment can improve the transportability
of evidence-based practice from research to real-world
clinical environments, and it lowers many of the barriers
people face to accessing care. The technology also offers a
level of convenience not generally available via therapist-
delivered treatment (such as 24-hour access to treatment,
no wait-lists). Within a stepped-care framework, CBPT
offers an alternate entry point into mainstream treat-
ment or a credible alternative for people who cannot or
choose not to seek treatment from existing mental
health services [3,4].
The potential benefits of CBPT for clinicians and the
broader health care system are equally significant. Demand
for psychological treatment outstrips supply, particularly in
regional and rural communities. By delegating parts of
treatment to a computer, clinicians may be able to redirect
their time and expertise toward those patients who require
more intensive and/or specialist intervention [4]. Marks
and colleagues [5] compared treatment outcomes for
people with panic disorder receiving computer-delivered,
therapist-delivered, or combined therapist/computer-
delivered treatment. By delegating self-exposure tasks
to a computer, clinicians reduced the amount of face-to-
face time per client by 73 percent, without compromising
treatment outcomes [5].
Kay-Lambkin and colleagues [6] developed and evaluated
a CBPT package for co-existing depression and alcohol/
drug use disorders: SHADE (Self-Help for Alcohol and
other drug use and DEpression). After completing a face-
to-face assessment comprising feedback, case formulation,
and initial goal setting, participants (n = 97) were randomly
allocated to either: 1) therapist-delivered cognitive behav-
ioral therapy (CBT) and motivational interviewing (MI); 2)
integrated computer-delivered CBT/MI (i.e., SHADE plus
brief weekly therapist assistance); or 3) one session of
feedback and case formulation delivered face to face as
the control condition (brief intervention). The study foundno significant differences between the intensive therapist-
delivered CBT/MI and that delivered primarily via the
SHADE computer program, with significant improve-
ments in depression, drug use, and quality-of-life mea-
sures for both conditions at 12-month follow-up. Both
CBT/MI conditions (therapist- and computer-delivered)
were associated with greater (nonsignificant) reductions in
depression, alcohol, and cannabis use relative to the brief
intervention condition, with computer-delivered SHADE
treatment associated with greater (nonsignificant) reduc-
tions in cannabis use over the other treatment conditions.
Computer-delivered SHADE treatment required on aver-
age 12.5 minutes of generic face-to-face time per session,
compared to 60 minutes of specialist psychologist input
for the therapist-delivered CBT/MI treatment. A study
examining client acceptability of the SHADE program
found that people receiving CBPT are equally able to
engage, bond, and commit to treatment as those receiving
therapist-delivered treatment [7].
In a replication of the initial SHADE study [8], 274
participants were recruited across seven urban and rural
communities, but using a different active control condi-
tion of 10 sessions of supportive counseling (face to face,
without any CBT/MI strategies) rather than the brief
intervention control. Like the initial study, computer- and
intensive therapist-delivered CBT/MI were associated with
superior reductions in depression, alcohol, and cannabis
use compared to supportive counseling, indicating that
improvements were not simply the product of nonspecific
effects. This research promises much for the practical
application of CBPT, particularly the SHADE program,
as an additional strategy in the treatment of co-existing
depression and drug use problems. CBPT has the poten-
tial to be a ‘clinician extender’ and sit credibly along a
continuum of evidence-based psychological care [5].
Despite the potential and emerging evidence for CBPT,
its uptake into clinical practice has been low [9,10]. This
may be due to the scarcity of research into the barriers,
expectations, and experiences of both clinicians and clients
when using CBPT in a clinical setting [11].
As with any treatment, there will be a range of client-
and clinician-level factors influencing the uptake, use,
and impact of CBPT. It remains unclear if the technol-
ogy will realize its potential. Our study set out to
complete an observational field study of CBPT use,
namely the SHADE resource, in a community-based
drug and alcohol clinical service. Our primary aim was
to observe if, when, and how clinicians might utilize
SHADE in their clinical practice, following provision of
a 2-hour information and training session on the
SHADE program. We aimed to understand the relation-
ship between use of the SHADE program and clinician
attitudes towards technology. We also set out to explore
changes in key outcomes for clients exposed to the
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clients to use CBPT in their treatment.
Methods
Setting and design
The study was undertaken in collaboration with the Central
Coast Alcohol and Other Drug Service (CCAODS), a sub-
sidiary of the Northern Sydney Central Coast Area Health
Service. CCAODS delivers a wide range of AOD treatment
services, including inpatient and community detoxification,
pharmacotherapy programs, general counseling, medical
services, a court-mandated diversion program for people
with drug use problems and concurrent legal issues
(Magistrates Early Referral Into Treatment; MERIT), as
well as a specialist program for clients with a primary
drug concern of marijuana misuse/dependency (Cannabis
Clinic). The service also provides general practitioner
liaison, health promotion, community consultation, and
an Aboriginal liaison services. A central intake service
acts as the point of initial contact with the CCAODS,
with referrals being forwarded to relevant departments.
The type of psychological intervention provided by
clinical staff is not prescribed. All clients entering the
service complete a standardized intake assessment. All
CCAODS clinicians attend regular review sessions and
compulsory clinical supervision.
Eight desktop computers were supplied to the CCAODS
for the duration of the study. Each computer had the
SHADE–CBPT program pre-installed onto its hard drive.
These computers were not connected to the internet. No
conditionality or instructions were supplied with the
computers, and clinicians were free to make use of the
computers however they wished. Most counseling rooms
also had an internet-compatible desktop computer. An
unlimited supply of SHADE DVDs was also made avail-
able throughout the study for clients to take home and
complete at the discretion of the clinician. Clients did not
have to participate in the research to use SHADE.
The study was employed as an observational study of
clinician implementation of SHADE with current and
ongoing clients in their caseload, following a 2-hour
information and training session on the resource.
SHADE – computer-based psychological treatment
The SHADE–CBPT program has been described elsewhere
[6,8]. SHADE incorporates CBT/MI strategies to encourage
reductions in depression and AOD use. SHADE is available
in two formats: 1) a 10-session program designed to
be completed in a linear fashion, with content pre-
programmed for each session; or 2) a skill module pro-
gram, where a series of shorter modules are presented
based on themes related to depression and AOD use
problems (e.g., coping with cravings, taking charge of one’s
thoughts, staying well) arising from the 10-week program.Clients or clinicians are able to select a particular skill
module to focus on during a session, without having to
complete the other skills and strategies contained in the
resource. Both versions of SHADE were made available for
the study. Text is pitched at a reading age of 14 years, with
a voiceover available to read out all text contained in the
resource. Video case scenarios guide clients through a
range of CBT/MI skills and strategies, and accompanying
handouts and worksheets are also available for clients/




All clinicians (n = 13) working within the CCAODS – Drug
and Alcohol Counseling, Cannabis Clinic, and MERIT
teams were invited to participate in the study. All clinicians
had tertiary qualifications in a counseling-related field,
with at least an undergraduate degree in nursing or
psychology. The group reported a mean age of 42.90 years
(SD = 11.17, range 25–58) and were, for the most part,
female (n = 11/13). Clinicians provided assessment and
treatment according to evidence-based psychosocial
guidelines established for their service [12].
Clients
All new and existing adult clients seeking treatment
from CCAODS’ Drug and Alcohol Counseling, Cannabis
Clinic, and MERIT services were recruited for a larger
study of treatment outcomes in the service, with separate
consent and assessment procedures provided through
their clinician [13]. The study team was responsible for
recruiting clients into the study, based on a referral from
their treating clinician to the research team. To preserve
anonymity and the confidentiality of participants and
assessment results, clinicians were not aware of the par-
ticipation status of their clients in the trial; in addition,
clinicians were asked to submit session checklists for
all clients throughout the study period.
Measures
The assessment tools used as part of the study are widely
used in mental health and/or AOD treatment research and
practice. A full description of the study methods has been
published previously [13]. Ethics approval for the study was
obtained from Northern Sydney Central Coast Human
Research Ethics Committee (08/HARBR/78/79), the Uni-
versity of Newcastle Human Research Ethics Committee
(H-2008-0271), and the Macquarie University Ethics
Review Committee (Human Research, 0806-125 M(R)).
Clinician measures
The following measures were completed at baseline only,
prior to receipt of any CBPT material:
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using a 7-point Likert scale assessing the likelihood of an
individual to adopt innovative strategies in their work.
The more innovative an individual believes they are, the
higher their score on the IOS. Scores on the IOS range
from 20 to 140. The IOS has a reliability of 0.94, with
acceptable construct and predictive validity. The measure
has an internal consistency reliability of 0.88.
Computer Opinion Survey (CAIN) – a measure of com-
puter anxiety and a proxy criterion for how comfortable
clinicians are with adopting and using CBPT. The CAIN
is a 26-item measure using a 6-point Likert scale, with
scores ranging from 26 (the highest level of computer
anxiety) to 156 (measure of least computer anxiety).
Internal consistency of the scale is 0.94, with test/retest
reliability of 0.90 [15].
Client measures
Demographic details (e.g., age, gender, employment status,
mental health treatment history) were recorded at
baseline. Client assessment collected at baseline and at
15-week follow-up included:
Opiate Treatment Index OTI [16]; – The OTI assesses
the quantity and frequency of use for 11 different drugs,
including: alcohol, cannabis, heroin, other opiates, amphet-
amines, cocaine, hallucinogens, barbiturates, tranquilizers,
inhalants, and tobacco. Each of the 11 drug types are
assessed individually, and clients report on their last
three using occasions in the month prior to assessment,
estimating the amount of drug consumed on each of
these occasions. An average use index for the previous
month is calculated for each drug. Use of alcohol and
cannabis, the most frequently reported drugs used by
clients of the service, are reported here.
Depression Anxiety Stress Scale, 21-item version DASS-
21 [17]; – The DASS-21 was used to measure depression,
anxiety, and stress scores for the 2 weeks prior to assess-
ment. The scale has a Cronbach alpha of 0.93 for the total
measure, as well as high reliability for the subscales of
stress, depression, and anxiety (0.93, 0.90, and 0.82,
respectively) [18].
Previous experience of computers/the internet for AOD
treatment and openness to integrating technology into
current treatment plan – At baseline, clients were asked a
series of questions about their previous computer experi-
ence and their willingness to try computerized treatments
in their current AOD treatment program.
Procedures
Clinicians
Clinicians attached to each of the counseling teams par-
ticipating in the study attended an information session
facilitated by the authors. Clinicians were provided with
an overview of the study, a brief appraisal of researchsupporting CBPT as a treatment option for mental health
problems (including AOD use problems), and a demon-
stration of the SHADE treatment program as an example.
The group discussed different ways in which SHADE
could be incorporated into the clinical practice, either
using the full 10-session program or individual SHADE
sessions (e.g., on relapse prevention, mindfulness, or pro-
blemsolving) to supplement the ongoing treatment plan.
This session lasted for 2 hours.
Throughout the study, participating clinicians completed
four key activities:
1. At baseline, and prior to receiving the CBPT training
session, clinicians completed two self-report measures
assessing their openness to innovation and computer
anxiety.
2. Following baseline assessment and receiving the
CBPT training session, clinicians were asked to
consider and use SHADE with new and ongoing
clients in whatever manner they chose.
3. Following baseline assessment and receiving the
CBPT training session, clinicians were asked to
forward the contact details for new and ongoing
clients to the research team throughout the study
period, regardless of their exposure to SHADE.
4. At the conclusion of each session during the study
period, the clinicians were asked to complete a
session checklist. The checklist collected information
about the focus and content of the session, including
whether or not SHADE was discussed, used in-session,
and/or recommended as a homework exercise. The
checklist was developed by the authors to specifically
suit the CCAODS and the range of counseling
interventions used by the clinicians.
Clients
The recruitment and consent process for clients was
conducted by the research team, independently from the
clinicians participating in the study. Following referral
from the clinicians in the CCAODS, the research team
contacted potential clients to discuss study participation
and obtain consent. Study participation involved com-
pleting a baseline and a 15-week follow-up assessment
delivered over the telephone by a research assistant, in-
dependent from the CCAODS. Clients were reimbursed
$20AUD for each completed assessment. For the current
study, eligible clients were those who provided consent
to participate in the baseline and 15-week follow-up
assessments and who had at least one clinician checklist
submitted to the team for analysis.
Data analysis
Data was analysed using SPSS, version 17.0 (SPSS Inc.,
Chicago, IL, USA).
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Descriptive statistics explored the self-reported use of
SHADE by clinicians involved in the project as a function
of primary drug of concern, and where and how it was
used in the treatment protocol.
Clinician innovation and computer anxiety
Descriptive statistics were used to explore the responses
of clinicians to these surveys, with one sampled t-test
employed to examine potential differences between score
on these scales in the sample, relative to the established
norms for each scale. Pearson correlation coefficients were
calculated to examine the relationship between scores on
the IOS and those on the CAIN.
Patterns of change in key client outcomes
Descriptive statistics summarized client responses to
prior computer use and their openness to receiving
computerized treatments in the current treatment
program, along with patterns of change in alcohol use,
cannabis use, depression, anxiety, and stress scores over
the study period.
Results
Client and clinician participants
Figure 1 displays the number of clinicians and clients
providing data for the study.
For the current analysis, eligible clients were those
for whom their treating clinician had submitted at least
one clinician checklist summarizing the session content
(N = 35). This represented 45 percent (35/77) of the clients
recruited to the larger study. The pool of eligible clients
(N = 35) reported a mean age of 42.11 years (SD = 12.152,
range 19–65) and included more males than females
(n = 22, 63% male).Figure 1 The number of clinicians and clients of a publicly funded drOf the eligible client pool (N = 35), a review of session
checklists revealed that 12 were exposed to the SHADE
program during their treatment period.Use of CBPT
Clinicians submitted session checklists for 35 clients over
the course of the study. Twelve of the 13 clinicians (92%)
reported use of the SHADE materials with a client. Clini-
cians reported using the SHADE program in one of three
ways:
1) Introducing and discussing the SHADE resource
with clients and recommending its use as part of the
client’s treatment plan (n = 3 clinicians);
2) Using the SHADE handouts and worksheets either
as homework or to supplement work done within
the session (n = 12 clinicians); or
3) Use of the full SHADE modules in-session to deliver a
specific psychological treatment/intervention (n = 11
clinicians). In this context, full SHADE modules were
used during the session, assigned as homework, or as
a combined in-session strategy and homework.
Twelve clients (12/35, 34%) were exposed to the full
SHADE modules.
If full SHADE modules were used, they were generally
introduced in the early phase of treatment; on average,
at session 4 (M = 3.77, SD = 5.26, range 1–36). Of the
exposed clients (n = 12), an average of 5 of the 10 SHADE
modules were completed. If SHADE was discussed rather
than the full module being incorporated into sessions,
this tended to be later in the treatment experience, and
on average was reported during sessions 5–6 (M = 5.26,
SD = 8.39, range 1–33).ug and alcohol service who provided data for the current study.
Table 1 Changes in key client outcomes between baseline









No exposure to SHADE (n = 23) 6.58 (8.30) 3.90 (4.15)
Exposure to SHADE (n = 12) 11.81 (20.17) 3.76 (4.27)
Cannabis use
No exposure to SHADE (n = 23) 11.15 (9.77) 7.93 (9.17)
Exposure to SHADE (n = 12) 18.63 (16.84) 9.94 (6.33)
Depression*
No exposure to SHADE (n = 23) 20.69 (2.71) 11.09 (2.11)
Exposure to SHADE (n = 12) 19.83 (3.76) 11.17 (2.93)
Anxiety*
No exposure to SHADE (n = 23) 11.48 (2.50) 8.44 (2.04)
Exposure to SHADE (n = 12) 14.17 (3.46) 8.83 (2.83)
Stress*
No exposure to SHADE (n = 23) 22.35 (2.13) 14.17 (2.00)
Exposure to SHADE (n = 12) 24.00 (2.95) 14.50 (2.76)
*Subscale scores on the Depression Anxiety Stress Scale 21 [18].
Kay-Lambkin et al. Addiction Science & Clinical Practice 2014, 9:15 Page 6 of 9
http://www.ascpjournal.org/content/9/1/15Clinician openness to innovation
Clinicians in the study reported an average innovation
score on the IOS of 97.62 (SD = 14.32, range 72–130). On
average, this was lower than the established norm for the
scale of 102, but this difference was not statistically signifi-
cant (t(12) = −1.104, p = 0.291). Mean IOS scores were
97.92 (SD = 14.95) for 12 clinicians utilizing SHADE in
their sessions with clients, with the one clinician choosing
not to use SHADE and scoring 94.00 on this scale.
Clinician trait computer anxiety
Clinicians were relatively low on computer-related anxiety,
scoring an average of 120.38 on the CAIN (SD = 17.65,
range 91–148). The group rated themselves significantly
lower on computer anxiety than did those in the norma-
tive sample for the scale (120.38 vs. 105.4, t (12) = 3.046,
p = 0.010). The clinician not using SHADE in sessions
reported a CAIN score of 108.00, with the 12 clinicians
utilizing SHADE reporting a mean of 121.33 (SD = 18.02),
with higher scores indicating lower levels of anxiety.
There was not a significant relationship found between
scores on the CAIN and scores on the IOS for the sample,
indicating no relationship between clinician innovation
and computer anxiety (r = 0.455, p = 0.188).
Willingness to use CBPT
Of the 35 eligible clients for the current study, 31 per-
cent (n = 11) reported previously using computers or the
internet to search for information and treatment for a
mental health or AOD use problem. Thirty-three clients
(94%) felt that integrating a computer-based program
into their current treatment plan would be “a little”
through to “very” helpful in treating their current AOD
use problems. The majority of clients (n = 28/35, 80%)
felt that if they were offered access to a computer-based
treatment program during their current treatment plan,
they would definitely utilize it, leaving seven clients (20%)
not prepared to consider using this form of treatment.
For these seven clients, four reported they “didn’t like
technology” or were “computer illiterate,” with the
remaining three preferring human contact over that
with a computer program.
Of the 35 eligible clients, 12 were exposed to the full
SHADE modules, five were exposed to just the SHADE
handouts or worksheets rather than a full module, and
three has the SHADE resources mentioned to them
during a session. Twelve (34%) would have used CBPT,
but were not exposed, and three (9%) were unwilling to
use CBPT but were exposed to the SHADE handouts or
worksheets.
Patterns of change in key client outcomes
For alcohol use between baseline and 15-week follow-up
assessment, participants who did not receive the SHADEmodules (n = 23) reported a 3-standard-drink per day re-
duction in alcohol use between baseline and at 15-week
follow-up assessment, while those who were exposed to
SHADE (n = 12) reported an 8-standard-drink per day
reduction over the same time period.
Clients reported reductions in cannabis use between
baseline and 15-week follow-up. For those exposed to
the SHADE resource during treatment (n = 12), this was
a reported 9-standard-use per day reduction in cannabis
use over time, relative to a 3-standard-use per day reduc-
tion in those daily users not exposed to SHADE (n = 23).
Table 1 displays the changes in depression, anxiety, and
stress scores measured by the DASS-21 over time as a
function of use of the SHADE material, along with the
changes in alcohol and cannabis use for all eligible
participants (N = 35).
Discussion
Improving access to evidence-based treatments for
mental health disorders, including AOD problems, is a
significant health care priority. CBPT offers potential to
address this need. Our study set out to observe how
AOD clinicians used CBPT in a real-world clinical
setting.
Utilization of SHADE
Over the course of the study, 12 of the 13 participating
clinicians introduced SHADE to their clients, in some
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the 77 consenting to participate in the larger study) who
were exposed to at least one full SHADE module (average
of 5 of the 10 SHADE sessions). CBPT was commonly
introduced to clients early in treatment, most commonly
during session 4. This pattern of use may indicate the
need for clinicians to establish rapport with their clients
prior to suggesting CBPT, and perhaps for immediate
crisis-related issues to be addressed first. Some clinicians
did introduce SHADE for clients already engaged in
treatment (i.e., 10 sessions attended or more); however,
most often it was via the use of handouts or worksheets
produced by the SHADE program, rather than delegating
parts of treatment to CBPT. Our results echo an earlier
study indicating that, in the absence of incentives or
encouragement from researchers, AOD clinicians tend
to refer only a small proportion of their caseload to
CBPT [11]. During the 2-hour training and information
session provided to clinicians on the SHADE resource,
no direct or specific advice was provided as to when or
how clinicians should use the program with clients.
Clinicians were asked to consider using SHADE with all
of their clients, at their discretion, and were provided with
scenarios during the training that included using the
full 10-session version of the program, using one or
two individual modules of the program to supplement
their existing treatment plan. It is interesting that each
clinician seems to have used SHADE with only one client
from their caseload (e.g., 12 clinicians reporting use of
SHADE, 12 clients exposed to SHADE). It is possible that
clinicians operationalized their commitment to the study
as using the SHADE resource with at least one client,
rather than this being the minimum. In the context of a
busy clinical service, this is not surprising; however, it
highlights the challenges clinicians and researchers face in
attempting to disseminate new approaches into existing
care practices.
From the client’s perspective, self-reported willingness
to use CBPT in their current treatment program was
much higher than perhaps their clinicians anticipated
(80% willing, but 34% exposed). This meant that 12
additional clients would have utilized SHADE, if offered,
to assist them in managing their AOD use concerns.
Clients willing to use SHADE tended to use cannabis at
a higher level than their “unwilling” counterparts and
reported more symptoms of stress on the DASS. Although
a much larger study is required to properly test these
trends, our results suggest that cannabis users and those
feeling under stress might be more open to taking on
SHADE. Previous research has indicated that, indeed,
people using cannabis with comorbid depression do
report superior improvements in cannabis use and
depressive symptoms after receiving SHADE over face-to-
face treatments [8] and that cannabis users in drug andalcohol treatment settings may be more suited to non
face-to-face interventions [19].
Client self-reported depression, anxiety, stress, and
alcohol and cannabis use declined over the study period.
On average, alcohol and cannabis use, anxiety, and stress
levels tended to be higher in clients who were exposed to
the SHADE modules. It may be that severity of symp-
toms/AOD use served as the impetus for clinicians to use
SHADE to augment their treatment with clients whose
consumption of alcohol or cannabis was high or whose
levels of anxiety or stress (but not depression) were high.
Clinician openness to innovation, computer anxiety, and
therapeutic alliance
Openness to innovation
There is little research to guide the description of inno-
vativeness for mental health clinicians, crucial to the
uptake of CBPT. While drug and alcohol clinicians are
generally open to new and better treatments, most inno-
vations find it difficult to make their way into clinical
practice [20]. Generating new evidence-based treatments
is not the most significant challenge for researchers;
rather, it is increasingly seen that encouraging adoption
and integration of evidence-based treatments into clin-
ical practice is key [21]. Our study results indicate that
while the clinicians in our study were above the norm
on their readiness to accept and use technology and
innovation in their clinical practice, this did not translate
directly into the use of SHADE modules with the majority
of their clients.
Computer anxiety
To our knowledge, no research has previously attempted
to measure computer anxiety (or computer comfort)
among AOD clinicians. There is, instead, a small body of
research examining clinician perceptions and technological
attitudes toward CBPT, albeit not in an AOD context [22].
As a group, participating clinicians in our study reported
having relatively low-level computer anxiety. This would
suggest that computer technology or the thought of using
computer technology did not present as a limiting factor
on a clinician’s decision to utilize SHADE during the study.
Limitations and recommendations for future research
There are several limitations to the current study that
are important to mention, not the least of which is the
small sample size (clinicians and clients) and relatively
small number of sessions available for examination. In
addition, the data collection did not include an external
check on client exposure to CBPT, and we are unable to
verify the proportion of sessions for which clinician
checklists were submitted versus all sessions conducted
with clients. Instead, we used self-report data supplied
by clinicians via a session-by-session checklist. Clinicians
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every client seen in every treatment session during the
study period; but, for ethical reasons, we were unable to
establish how compliant clinicians were with this request.
Service data indicate that, on average, clients attend 4.5
treatment sessions per occasion of service with the
CCAODS [23], suggesting that for clients engaged in our
study (n = 77), we should have received approximately 347
clinician checklists over our 6-month recruitment period.
Clinicians in our study submitted 304 clinician checklists,
which is close to this estimate. As previously reported
[23], we received 123 referrals to the project during the
6-month recruitment phase, resulting in 77 consenting
clients for the larger study. Over a 2-year period, the
CCAODS received 1,684 referrals to the service across 11
teams (including acute, nonacute, inpatient, and out-
patient services). We targeted three teams from CCAODS
for participation in the study. Based on these data, 459
referrals would have been received by these three teams
over a 2-year period, or 115 over a 6-month period. We
are therefore reasonably confident that clinicians referred
most, if not all, clients they saw during the 6-month
period for participation in the study.
Clinicians were invited by research staff to participate
in the study, and all clinicians associated with our target
service consented to participate. Consequently, the risk of
selection bias may limit the generalizability of the findings.
We also collected data from one treatment setting only
that was staffed by relatively skilled and experienced
clinicians. It is of note that we also only accessed clients
who were already attending a drug and alcohol clinical
service and therefore could not determine the unique
contribution (if any) of CBPT over usual treatment. It
remains unclear whether the results from this study
would generalize across other drug and alcohol clinical
services. Fully powered CBPT dissemination trials in
different settings with different clinical groups are required.
It would also be interesting to explore the use of CBPT
among wait-list clients for drug and alcohol clinical ser-
vices (i.e., clients who have sought treatment but have yet
to attend their first treatment session). This was planned
for the current study, but was unable to be implemented
during the study period.
Conclusion
In a small way, this study has contributed to our under-
standing of the factors that might influence a clinician’s
decision to integrate CBPTs into their treatment plan.
Clinicians were open to innovation, not anxious about
using computers or technology, yet still only chose to
utilize SHADE with 34 percent of clients. It has previously
been suggested that eHealth in general, and CBPT in
particular, is not only a “technical development, but also
a state-of-mind…an attitude, and a commitment…” tousing technology to improve health care [24]. The results
of this study seem to support this notion, and point to the
importance of committing significant support to adopt
any new innovation, particularly CBPT.
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